July 2022—BioMérieux announced the CE marking of its Vidas Anti-Chikungunya IgM and Anti-Chikungunya IgG tests to diagnose Chikungunya virus infection. The tests can detect infection during the acute phase and into the chronic phase and run on the company’s Vidas immunoassay instruments.
Pages: 1 2